Bio-Techne Corp TECH
72.61
0.04
0.06%
as of 25 Sep
- Market cap
- $11.4B
- P/E
- 62.1×
Follow TECH
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Bio-Techne Corp (TECH) Revenue growth
Bio-Techne Corp's revenue growth over the twelve months to 30 June 2026 was −0.38%. Over the past ten years it has ranged from −0.38% (fiscal 2026) to 26.4% (fiscal 2015) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 5.64% and below the Healthcare sector median of 8.26%.
Revenue growth, annual
Annual
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2026 | −0.38% | (5.61) |
| FY2025 | 5.23% | 3.26 |
| FY2024 | 1.97% | (0.84) |
| FY2023 | 2.81% | (15.94) |
| FY2022 | 18.8% | (7.29) |
| FY2021 | 26.0% | 22.58 |
| FY2020 | 3.46% | (7.58) |
| FY2019 | 11.0% | (3.17) |
| FY2018 | 14.2% | 1.39 |
| FY2017 | 12.8% | 2.48 |
Quarterly
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | 1.33% | 2.84 |
| Mar 2026 | −1.51% | (1.12) |
| Dec 2025 | −0.39% | 0.61 |
| Sep 2025 | −1.00% | (4.55) |
| 42 more quarters | Free account |
Against its own ten years
Low −0.38%
High 26.4%
Ten-year median
10.7%
Current reading's percentile
8
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| BBIO BridgeBio Pharma, Inc. compare | 202.4% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 149.0% |
| AXSM Axsome Therapeutics, Inc. compare | 56.9% |
| HALO Halozyme Therapeutics, Inc. compare | 41.2% |
| KRYS Krystal Biotech, Inc. compare | 22.6% |
| CORT Corcept Therapeutics Incorporated compare | 16.0% |
| BMRN BioMarin Pharmaceutical Inc. compare | 11.2% |
| TECH Bio-Techne Corp | −0.38% |
| SMMT Summit Therapeutics PLC compare | −61.0% |
| Biotechnology industry median | 5.64% |
| Healthcare sector median | 8.26% |
| Market median | 7.41% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on TECH
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- The full statement